ICU Medical, Inc. (NASDAQ:ICUI) Stock Holdings Raised by Gotham Asset Management LLC

Gotham Asset Management LLC lifted its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 22.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 40,610 shares of the medical instruments supplier’s stock after buying an additional 7,410 shares during the period. Gotham Asset Management LLC owned 0.17% of ICU Medical worth $6,301,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. FORA Capital LLC bought a new stake in shares of ICU Medical during the 4th quarter valued at about $488,000. Deutsche Bank AG grew its position in shares of ICU Medical by 41.1% during the 4th quarter. Deutsche Bank AG now owns 21,792 shares of the medical instruments supplier’s stock valued at $3,381,000 after buying an additional 6,345 shares during the last quarter. Algert Global LLC grew its position in shares of ICU Medical by 16.9% during the 4th quarter. Algert Global LLC now owns 6,370 shares of the medical instruments supplier’s stock valued at $988,000 after buying an additional 920 shares during the last quarter. Freestone Grove Partners LP bought a new stake in shares of ICU Medical during the 4th quarter valued at about $368,000. Finally, Northern Trust Corp grew its position in shares of ICU Medical by 11.1% during the 4th quarter. Northern Trust Corp now owns 402,342 shares of the medical instruments supplier’s stock valued at $62,431,000 after buying an additional 40,187 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ICUI shares. StockNews.com downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research note on Tuesday, April 8th. Raymond James reduced their target price on shares of ICU Medical from $197.00 to $187.00 and set a “strong-buy” rating for the company in a research note on Friday, May 9th. Finally, KeyCorp reduced their target price on shares of ICU Medical from $209.00 to $191.00 and set an “overweight” rating for the company in a research note on Monday, April 21st. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $192.67.

Insider Transactions at ICU Medical

In other news, Director David C. Greenberg sold 1,942 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the sale, the director now directly owns 6,760 shares of the company’s stock, valued at approximately $971,141.60. This represents a 22.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 1.50% of the company’s stock.

ICU Medical Trading Down 0.5%

ICU Medical stock opened at $143.59 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The firm has a 50-day moving average price of $140.71 and a two-hundred day moving average price of $154.69. The firm has a market capitalization of $3.53 billion, a price-to-earnings ratio of -31.42 and a beta of 0.87. ICU Medical, Inc. has a 52-week low of $100.91 and a 52-week high of $196.26.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.49. The firm had revenue of $599.49 million during the quarter, compared to analyst estimates of $574.15 million. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. ICU Medical’s revenue was up 6.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.96 EPS. Sell-side analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.